Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
Add more filters










Publication year range
1.
Biomolecules ; 13(6)2023 06 05.
Article in English | MEDLINE | ID: mdl-37371523

ABSTRACT

Melatonin is a fascinating molecule that has captured the imagination of many scientists since its discovery in 1958. In recent times, the focus has changed from investigating its natural role as a transducer of biological time for physiological systems to hypothesized roles in virtually all clinical conditions. This goes along with the appearance of extensive literature claiming the (generally) positive benefits of high doses of melatonin in animal models and various clinical situations that would not be receptor-mediated. Based on the assumption that melatonin is safe, high doses have been administered to patients, including the elderly and children, in clinical trials. In this review, we critically review the corresponding literature, including the hypotheses that melatonin acts as a scavenger molecule, in particular in mitochondria, by trying not only to contextualize these interests but also by attempting to separate the wheat from the chaff (or the wishful thinking from the facts). We conclude that most claims remain hypotheses and that the experimental evidence used to promote them is limited and sometimes flawed. Our review will hopefully encourage clinical researchers to reflect on what melatonin can and cannot do and help move the field forward on a solid basis.


Subject(s)
Melatonin , Animals , Melatonin/pharmacology , Melatonin/therapeutic use , Mitochondria
2.
Cell Signal ; 35: 118-128, 2017 07.
Article in English | MEDLINE | ID: mdl-28389413

ABSTRACT

The influence of cell confluence on the ß-adrenoceptor (ß-AR)/cAMP/phosphodiesterase (PDE) pathway was investigated in cultured rat aortic smooth muscle cells (RASMCs). Cells were plated either at low density (LD: 3·103cells/cm2) or high density (HD: 3·104cells/cm2) corresponding to non-confluent or confluent cells, respectively, on the day of experiment. ß-AR-stimulated cAMP was monitored in real-time using the fluorescence resonance energy transfer (FRET)-based cAMP sensor, Epac2-camps. A brief application (15s) of the ß-AR agonist isoprenaline (Iso) induced a typical transient FRET signal, reflecting cAMP production followed by its rapid degradation. The amplitude of this response, which increased with the concentration of Iso (10 or 100nM), was higher in HD than in LD cells, whatever the Iso concentration used. However, activation of adenylyl cyclase by L-858051 (100µM) induced a similar saturating response in both LD and HD cells. A ß1-AR antagonist (CGP 20712A, 100nM) reduced the Iso (100nM) response in HD but not LD cells, whereas a ß2-AR antagonist (ICI 118,551, 5nM) reduced this response in HD cells and almost abolished it in LD cells. Competitive [125I]-ICYP binding experiments with betaxolol, a ß-AR ligand, identified two binding sites in HD cells, corresponding to ß1- and ß2-ARs with a proportion of 11% and 89%, respectively, but only one binding site in LD cells, corresponding to ß2-ARs. Total cAMP-PDE activity (assessed by a radioenzymatic assay) was increased in HD cells compared to LD cells. This increase was associated with a rise in mRNA expression of five cAMP-PDEs subtypes (PDE1A, 3A, 4A, 4B and 7B) in HD cells, and a decrease in basal [cAMP]i (assessed by an EIA assay). PDE4 inhibition with Ro-20-1724 (10µM) strongly prolonged the Iso response in LD and HD cells, whereas PDE3 inhibition with cilostamide (1µM) slightly prolonged Iso response only in LD cells. Interestingly, inhibition of PDE4 unmasked an effect of PDE3 in HD cells. Our results show that in cultured RASMCs, the ß-AR/cAMP/PDE signalling pathway is substantially modulated by the cell density. In HD cells, Iso response involves both ß1- and ß2-AR stimulation and is mainly controlled by PDE4, PDE3 being recruited only after PDE4 inhibition. In LD cells, Iso response involves only ß2-AR stimulation and is controlled by PDE4 and to a lower degree by PDE3. This low density state is associated with an absence of membrane expression of the ß1-AR, a lower cAMP-PDE activity and a higher basal [cAMP]i. This study highlights the critical role of the cellular environment in controlling the vascular ß-AR signalling.


Subject(s)
Cyclic Nucleotide Phosphodiesterases, Type 3/genetics , Myocytes, Smooth Muscle/metabolism , Receptors, Adrenergic, beta/genetics , Signal Transduction/genetics , Animals , Aorta/drug effects , Aorta/metabolism , Colforsin/analogs & derivatives , Colforsin/pharmacology , Cyclic AMP/genetics , Cyclic AMP/metabolism , Cyclic Nucleotide Phosphodiesterases, Type 3/metabolism , Cyclic Nucleotide Phosphodiesterases, Type 4/genetics , Cyclic Nucleotide Phosphodiesterases, Type 4/metabolism , Diterpenes , Fluorescence Resonance Energy Transfer , Imidazoles/pharmacology , Isoproterenol/pharmacology , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Myocytes, Smooth Muscle/drug effects , Phosphodiesterase 3 Inhibitors/pharmacology , Phosphodiesterase 4 Inhibitors/administration & dosage , Propanolamines/pharmacology , Rats , Receptors, Adrenergic, beta/metabolism , Signal Transduction/drug effects
3.
Gene Ther ; 21(7): 638-44, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24784449

ABSTRACT

Leptin targets specific receptors (OB-R) expressed in the hypothalamus to regulate energy balance. Leptin decreases food intake in normal weight individuals, but this effect is blunted in obese subjects who are characterized by a state of leptin resistance. The prevention of leptin resistance is one of the major goals of obesity research. Recently, we identified endospanin 1 as a negative regulator of OB-R, which by interacting with OB-R retains the receptor inside the cell. We show here that in obese mice endospanin 1 is upregulated in the hypothalamic arcuate nucleus (ARC), the major brain structure involved in body weight regulation, suggesting that endospanin 1 is implicated in obesity development and/or the installation of leptin resistance. In contrast, silencing of endospanin 1 with lentiviral vectors in the ARC of obese mice fully restores leptin responsiveness when combined with a switch to ad libitum fed chow diet. The recovery of central leptin sensitivity is accompanied by sustained body weight loss and amelioration of blood lipid parameters and steatosis. Collectively, our results define endospanin 1 as a novel therapeutic target against obesity.


Subject(s)
Arcuate Nucleus of Hypothalamus/metabolism , Carrier Proteins/metabolism , Leptin/metabolism , Obesity/metabolism , Animals , Carrier Proteins/genetics , Diet, High-Fat , Gene Expression Regulation , Intracellular Signaling Peptides and Proteins , Lipids/blood , Male , Mice , Mice, Inbred C57BL , Mice, Obese , STAT3 Transcription Factor/metabolism , Weight Loss
4.
J Neuroendocrinol ; 24(5): 798-808, 2012 May.
Article in English | MEDLINE | ID: mdl-22512326

ABSTRACT

GPR50, formerly known as melatonin-related receptor, is one of three subtypes of the melatonin receptor subfamily, together with the MT(1) and MT(2) receptors. By contrast to these two high-affinity receptor subtypes and despite its high identity with the melatonin receptor family, GPR50 does not bind melatonin or any other known ligand. Specific and reliable immunological tools are therefore needed to be able to elucidate the physiological functions of this orphan receptor that are still largely unknown. We have generated and validated a new specific GPR50 antibody against the ovine GPR50 and used it to analyse the neuroanatomical distribution of the GPR50 in sheep, rat and mouse whole brain. We demonstrated that GPR50-positive cells are widely distributed in various regions, including the hypothalamus and the pars tuberalis of the pituitary, in all the three species studied. GPR50 expressing cells are abundant in the dorsomedial nucleus of the hypothalamus, the periventricular nucleus and the median eminence. In rodents, immunohistochemical studies revealed a broader distribution pattern for the GPR50 protein. GPR50 immunoreactivity is found in the medial preoptic area (MPA), the lateral septum, the lateral hypothalamic area, the bed nucleus of the stria terminalis, the vascular organ of the laminae terminalis and several regions of the amygdala, including the medial nuclei of amygdala. Additionally, in the rat brain, GPR50 protein was localised in the CA1 pyramidal cell layer of the dorsal hippocampus. In mice, moderate to high numbers of GPR50-positive cells were also found in the subfornical organ. Taken together, these results provide an enlarged distribution of GPR50 protein, give further insight into the organisation of the melatoninergic system, and may lay the framework for future studies on the role of the GPR50 in the brain.


Subject(s)
Brain/metabolism , Nerve Tissue Proteins/metabolism , Receptors, G-Protein-Coupled/metabolism , Rodentia/metabolism , Sheep/metabolism , Age Factors , Animals , Brain/anatomy & histology , Female , Male , Mice , Mice, Inbred C57BL , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/physiology , Rabbits , Rats , Rats, Wistar , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/physiology , Rodentia/anatomy & histology , Rodentia/genetics , Sheep/anatomy & histology , Sheep/genetics , Tissue Distribution
5.
Eur Psychiatry ; 27(5): 369-71, 2012 Jul.
Article in English | MEDLINE | ID: mdl-21565467

ABSTRACT

This case-control study found an association between Seasonal Affective Disorder (SAD) and a single nucleotide polymorphism (intronic rs2072621) of the gene encoding GPR50 (an orphan member of the G protein-coupled melatonin receptor subfamily) in females. This may represent a gender-specific risk factor and a molecular link between melatonin and SAD.


Subject(s)
Genes, X-Linked , Introns , Nerve Tissue Proteins/genetics , Polymorphism, Single Nucleotide , Receptors, G-Protein-Coupled/genetics , Seasonal Affective Disorder/genetics , Case-Control Studies , Female , Genetic Association Studies , Genetic Predisposition to Disease , Genotype , Humans , Male , Sex Factors
6.
Br J Pharmacol ; 154(6): 1182-95, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18493248

ABSTRACT

Melatonin is a neurohormone that has been claimed to be involved in a wide range of physiological functions. Nevertheless, for most of its effects, the mechanism of action is not really known. In mammals, two melatonin receptors, MT1 and MT2, have been cloned. They belong to the G-protein-coupled receptor (GPCR) superfamily. They share some specific short amino-acid sequences, which suggest that they represent a specific subfamily. Another receptor from the same subfamily, the melatonin-related receptor has been cloned in different species including humans. This orphan receptor also named GPR50 does not bind melatonin and its endogenous ligand is still unknown. Nevertheless, this receptor has been shown to behave as an antagonist of the MT1 receptor, which opens new pharmacological perspectives for GPR50 despite the lack of endogenous or synthetic ligands. Moreover, MT1 and MT2 interact together through the formation of heterodimers at least in cells transfected with the cDNA of these two receptors. Lastly, signalling complexes associated with MT1 and MT2 receptors are starting to be deciphered. A third melatonin-binding site has been purified and characterized as the enzyme quinone reductase 2 (QR2). Inhibition of QR2 by melatonin may explain melatonin's protective effect that has been reported in different animal models and that is generally associated with its well-documented antioxidant properties.


Subject(s)
Receptors, Melatonin/drug effects , Receptors, Melatonin/physiology , Signal Transduction/drug effects , Signal Transduction/physiology , Animals , Binding Sites/drug effects , Dimerization , Humans , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/physiology , Receptor, Melatonin, MT1/drug effects , Receptor, Melatonin, MT1/metabolism , Receptor, Melatonin, MT2/drug effects , Receptor, Melatonin, MT2/metabolism , Receptors, G-Protein-Coupled/genetics , Receptors, G-Protein-Coupled/physiology , Receptors, Melatonin/metabolism , Tissue Distribution
7.
Eur J Histochem ; 50(4): 311-6, 2006.
Article in English | MEDLINE | ID: mdl-17213040

ABSTRACT

The pineal hormone melatonin is involved in physiological transduction of temporal information from the light dark cycle to circadian and seasonal behavioural rhythms, as well as possessing neuroprotective properties. Melatonin and its receptors MT1 and MT2, which belong to the family of G protein-coupled receptors, are impaired in Alzheimer's disease (AD) with severe consequences to neuropathology and clinical symptoms. The present data provides the first immunohistochemical evidence for the cellular localization of the both melatonin receptors in the human pineal gland and occipital cortex, and demonstrates their alterations in AD. We localized MT1 and MT2 in the pineal gland and occipital cortex of 7 elderly controls and 11 AD patients using immunohistochemistry with peroxidase-staining. In the pineal gland both MT1 and MT2 were localized to pinealocytes, whereas in the cortex both receptors were expressed in some pyramidal and non-pyramidal cells. In patients with AD, parallel to degenerative tissue changes, there was an overall decrease in the intensity of receptors in both brain regions. In line with our previous findings, melatonin receptor expression in AD is impaired in two additional brain areas, and may contribute to disease pathology.


Subject(s)
Alzheimer Disease/metabolism , Occipital Lobe/metabolism , Pineal Gland/metabolism , Receptor, Melatonin, MT1/metabolism , Receptor, Melatonin, MT2/metabolism , Aged , Aged, 80 and over , Alzheimer Disease/pathology , Biomarkers/metabolism , Female , Humans , Immunoenzyme Techniques , Male , Middle Aged
8.
Minerva Endocrinol ; 28(4): 313-20, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14752401

ABSTRACT

Melatonin, the hormone of darkness, has been known for a long time to be a major regulator of energy homeostasis in hibernating animals. Much less is known about the role of melatonin in energy homeostasis in non-hibernating animals, including humans. In mammals, two specific melatonin receptor subtypes, MT1 and MT2, have been cloned and are known to be expressed at central and peripheral sites. Although a central regulation of energy homeostasis has been widely accepted for hibernating animals, the exact site of melatonin action remains still poorly defined. Central effects appear to be predominantly mediated by the MT1 subtype. Recently, several groups showed that melatonin may also have a direct effect on peripheral tissues involved in energy homeostasis such as pancreatic beta cell, hepatocytes and adipocytes. Both, the MT1 and MT2 subtypes appear to be involved. The respective contribution of central and peripheral effects of melatonin on energy homeostasis in vivo must be established in future studies.


Subject(s)
Hibernation/physiology , Homeostasis/physiology , Melatonin/physiology , Animals
9.
Br J Ophthalmol ; 86(9): 1053-7, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12185137

ABSTRACT

AIM: To examine the distribution of melatonin 1a (MT1) receptors in the human eye. METHODS: Seven normal human eyes were examined by immunohistochemical staining of paraffin sections, using an anti-MT1 primary antibody and an ABC detection system. RESULTS: MT1 receptor immunoreactivity (MT1-IR) was detected primarily in the inner segments of rods and cones and in retinal ganglion cells. In addition, MT1-IR was present in the adventitia of retinal arteries and veins, including the papillary region, but absent in ciliary and choroidal vessels. Mild staining of corneal endothelial cells and keratocytes was observed in all but two eyes. CONCLUSION: MT1-IR is present in various ocular tissues with the highest density in photoreceptor cells and ganglion cells. The physiological function of these receptors deserves further investigation.


Subject(s)
Eye/chemistry , Receptors, Cell Surface/analysis , Receptors, Cytoplasmic and Nuclear/analysis , Aged , Aged, 80 and over , Cornea/chemistry , Female , Humans , Male , Photoreceptor Cells/chemistry , Photoreceptor Cells/cytology , Receptors, Melatonin , Retina/chemistry , Retina/cytology , Retinal Ganglion Cells/immunology , Retinal Vessels/chemistry
10.
Endocrinology ; 142(10): 4264-71, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11564683

ABSTRACT

Several reports have demonstrated that the pineal hormone, melatonin, plays an important role in body mass regulation in mammals. To date, however, the target tissues and relevant biochemical mechanisms involved remain uncharacterized. As adipose tissue is the principal site of energy storage in the body, we investigated whether melatonin could also act on this tissue. Semiquantitative RT-PCR analysis revealed the expression of MT1 and MT2 melatonin receptor mRNAs in the human brown adipose cell line, PAZ6, as well as in human brown and white adipose tissue. Binding analysis with 2-[(125)I]iodomelatonin ((125)I-Mel) revealed the presence of a single, high affinity binding site in PAZ6 adipocytes with a binding capacity of 7.46 +/- 1.58 fmol/mg protein and a K(d) of 457 +/- 5 pM. Both melatonin and the MT2 receptor-selective antagonist, 4-phenyl-2-propionamidotetraline, competed with 2-[(125)I]iodomelatonin binding, with respective K(i) values of 3 x 10(-11) and 1.5 x 10(-11) M. Functional expression of melatonin receptors in PAZ6 adipocytes was indicated by the melatonin-induced, dose-dependent inhibition of forskolin-stimulated cAMP levels and basal cGMP levels with IC(50) values of 2 x 10(-9) and 3 x 10(-10) M, respectively. Modulation of the cGMP pathway by melatonin further supports functional expression of MT2 receptors, as this pathway was shown to be specific for that subtype in humans. In addition, long-term melatonin treatment of PAZ6 adipocytes was found to decrease the expression of the glucose transporter Glut4 and glucose uptake, an important parameter of adipocyte metabolism. These results suggest that melatonin may act directly at MT2 receptors on human brown adipocytes to regulate adipocyte physiology.


Subject(s)
Adipocytes/metabolism , Receptors, Cell Surface/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Cell Line, Transformed , Gene Expression Regulation , Humans , Melatonin/metabolism , Polymerase Chain Reaction , Receptors, Melatonin
11.
Neurosci Lett ; 308(1): 9-12, 2001 Jul 27.
Article in English | MEDLINE | ID: mdl-11445273

ABSTRACT

The pineal hormone melatonin has two major functions: as a transducer of the circadian day-night signal across the seasons, and as a vasoactive substance regulating cerebral circulation. The vasoconstrictive effects of melatonin have been postulated to be mediated by the melatonin 1a-receptor (MT1). The objective of this study was to provide the first immunohistochemical evidence for the localization of vascular MT1 in human control hippocampus compared to Alzheimer's disease (AD) patients, since regional blood flow impairments contribute to the neurodegenerative course of the disease. Both superficial and intrahippocampal arteries revealed MT1 immunoreactivity in adventitia in controls, which was distinctly increased in AD patients. The increased MT1 in AD may indicate a regulatory response to impaired melatonin levels in those patients, contributing to the regulation of cerebral circulation.


Subject(s)
Alzheimer Disease/metabolism , Cerebral Arteries/metabolism , Cerebrovascular Circulation/physiology , Hippocampus/metabolism , Melatonin/metabolism , Receptors, Cell Surface/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Vasoconstriction/physiology , Aged , Aged, 80 and over , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Cerebral Arteries/pathology , Cerebral Arteries/physiopathology , Hippocampus/blood supply , Hippocampus/physiopathology , Humans , Immunohistochemistry , Receptors, Melatonin , Up-Regulation/physiology
12.
J Biol Chem ; 276(3): 2007-14, 2001 Jan 19.
Article in English | MEDLINE | ID: mdl-11053408

ABSTRACT

To identify new proteins involved in erythropoietin (Epo) signal transduction, we purified the entire set of proteins reactive with anti-phosphotyrosine antibodies from Epo-stimulated UT7 cells. Antisera generated against these proteins were used to screen a lambdaEXlox expression library. One of the isolated cDNAs encodes Gbeta2, the beta2 subunit of heterotrimeric GTP-binding proteins. Gbeta and Galpha(i) coprecipitated with the Epo receptor (EpoR) in extracts from human and murine cell lines and from normal human erythroid progenitor cells. In addition, in vitro Gbeta associated with a fusion protein containing the intracellular domain of the EpoR. Using EpoR mutants, we found that the distal part of the EpoR (between amino acids 459-479) was required for Gi binding. Epo activation of these cells induced the release of the Gi protein from the EpoR. Moreover in isolated cell membranes, Epo treatment inhibited ADP-ribosylation of Gi and increased the binding of GTP. Our results show that heterotrimeric Gi proteins associate with the C-terminal end of the EpoR. Receptor activation leads to the activation and dissociation of Gi from the receptor, suggesting a functional role of Gi protein in Epo signal transduction.


Subject(s)
Heterotrimeric GTP-Binding Proteins/metabolism , Receptors, Erythropoietin/metabolism , Animals , Cytoplasm/metabolism , Erythropoietin/pharmacology , Humans , Mice , Protein Binding , Receptors, Erythropoietin/drug effects , Recombinant Proteins/metabolism , Tumor Cells, Cultured
14.
Mol Endocrinol ; 13(12): 2025-38, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10598579

ABSTRACT

Mel 1a melatonin receptors belong to the super-family of guanine nucleotide-binding regulatory protein (G protein)-coupled receptors. So far, interest in Mel 1a receptor signaling has focused mainly on the modulation of the adenylyl cyclase pathway via pertussis toxin (PTX)-sensitive G proteins. To further investigate signaling of the human Mel 1a receptor, we have developed an antibody directed against the C terminus of this receptor. This antibody detected the Mel 1a receptor as a protein with an apparent molecular mass of approximately 60 kDa in immunoblots after separation by SDS-PAGE. It also specifically precipitated the 2-[125I]iodomelatonin (125I-Mel)-labeled receptor from Mel 1a-transfected HEK 293 cells. Coprecipitation experiments showed that G(i2), G(i3), and G(q/11) proteins couple to the Mel 1a receptor in an agonist-dependent and guanine nucleotide-sensitive manner. Coupling was selective since other G proteins present in HEK 293 cells, (G(i1), G(o), G(s), G(z), and G12) were not detected in receptor complexes. Coupling of the Mel 1a receptor to G(i) and G(q) was confirmed by inhibition of high-affinity 125I-Mel binding to receptors with subtype-selective G protein alpha-subunit antibodies. G(i2) and/or G(i3) mediated adenylyl cyclase inhibition while G(q/11) induced a transient elevation in cytosolic calcium concentrations in HEK 293 cells stably expressing Mel 1a receptors. Melatonin-induced cytosolic calcium mobilization via PTX-insensitive G proteins was confirmed in primary cultures of ovine pars tuberalis cells endogenously expressing Mel 1a receptors. In conclusion, we report the development of the first antibody recognizing the cloned human Mel 1a melatonin receptor protein. We show that Mel 1a receptors functionally couple to both PTX-sensitive and PTX-insensitive G proteins. The previously unknown signaling of Mel 1a receptors through G(q/11) widens the spectrum of potential targets for melatonin.


Subject(s)
Receptors, Cell Surface/physiology , Receptors, Cytoplasmic and Nuclear/physiology , Signal Transduction , Adenylate Cyclase Toxin , Adenylyl Cyclase Inhibitors , Amino Acid Sequence , Animals , Calcium/metabolism , Cell Line , Cells, Cultured , Cytosol/metabolism , Humans , Melatonin/pharmacology , Molecular Sequence Data , Molecular Weight , Pertussis Toxin , Pituitary Gland, Anterior/drug effects , Pituitary Gland, Anterior/metabolism , Receptors, Cell Surface/chemistry , Receptors, Cell Surface/genetics , Receptors, Cytoplasmic and Nuclear/chemistry , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Melatonin , Sheep , Solubility , Transfection , Virulence Factors, Bordetella/pharmacology
15.
J Biol Chem ; 274(41): 28900-8, 1999 Oct 08.
Article in English | MEDLINE | ID: mdl-10506134

ABSTRACT

Sustained activation of most G protein-coupled receptors causes a time-dependent reduction of receptor density in intact cells. This phenomenon, known as down-regulation, is believed to depend on a ligand-promoted change of receptor sorting from the default endosome-plasma membrane recycling pathway to the endosome-lysosome degradation pathway. This model is based on previous studies of epidermal growth factor (EGF) receptor degradation and implies that receptors need to be endocytosed to be down-regulated. In stable clones of L cells expressing beta(2)-adrenergic receptors (beta(2)ARs), sustained agonist treatment caused a time-dependant decrease in both beta(2)AR binding sites and immuno-detectable receptor. Blocking beta(2)AR endocytosis with chemical treatments or by expressing a dominant negative mutant of dynamin could not prevent this phenomenon. Specific blockers of the two main intracellular degradation pathways, lysosomal and proteasome-associated, were ineffective in preventing beta(2)AR down-regulation. Further evidence for an endocytosis-independent pathway of beta(2)AR down-regulation was provided by studies in A431 cells, a cell line expressing both endogenous beta(2)AR and EGF receptors. In these cells, inhibition of endocytosis and inactivation of the lysosomal degradation pathway did not block beta(2)AR down-regulation, whereas EGF degradation was inhibited. These data indicate that, contrary to what is currently postulated, receptor endocytosis is not a necessary prerequisite for beta(2)AR down-regulation and that the inactivation of beta(2)ARs, leading to a reduction in binding sites, may occur at the plasma membrane.


Subject(s)
Receptors, Adrenergic, beta-2/metabolism , Adrenergic beta-2 Receptor Agonists , Animals , Binding Sites , Cell Line , Cell Membrane/metabolism , Cysteine Endopeptidases/metabolism , Down-Regulation , Dynamins , Endocytosis/drug effects , Epidermal Growth Factor/metabolism , GTP Phosphohydrolases/genetics , GTP Phosphohydrolases/metabolism , Gene Expression , Humans , Isoproterenol/pharmacology , L Cells , Lysosomes/metabolism , Mice , Microscopy, Fluorescence , Multienzyme Complexes/metabolism , Proteasome Endopeptidase Complex , Recombinant Fusion Proteins/metabolism , Serine Proteinase Inhibitors/pharmacology , Ubiquitins/metabolism
16.
Mol Pharmacol ; 56(5): 1014-24, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10531408

ABSTRACT

If stably expressed in human embryonic kidney (HEK)293 cells, the human Mel(1a)-melatonin receptor activates G(i)-dependent, pertussis toxin-sensitive signaling pathways, i.e., inhibition of adenylyl cyclase and stimulation of phospholipase Cbeta; the latter on condition that G(q) is coactivated. The antagonist luzindole blocks the effects of melatonin and acts as an inverse agonist at the Mel(1a) receptor in both intact cells and isolated membranes. This suggests that the Mel(1a) receptor is endowed with constitutive activity, a finding confirmed on reconstitution of the Mel(1a) receptor with G(i). Because the receptor density is in the physiological range, constitutive activity is not an artifact arising from overexpression of the receptor. In addition, the following findings indicate that the Mel(1a) receptor forms a very tight complex with G(i) which can be observed both in the presence and absence of an agonist. 1) In intact cells and in membranes, high-affinity agonist binding is resistant to the destabilizing effect of guanine nucleotides. 2) The ability to bind an agonist with high affinity is preserved even after exposure of the cells to pertussis toxin, because a fraction of G(i) is inaccessible to the toxin in cells expressing Mel(1a) receptors (but not the A(1)-adenosine receptor, another G(i)-coupled receptor). 3) An antiserum directed against the Mel(1a) receptor coprecipitates G(i) even in the absence of an agonist. We therefore conclude that the Mel(1a) receptor is tightly precoupled and that its constitutive activity may play a role in pacing the biological clock, an action known to involve the melatonin receptors in the suprachiasmatic nucleus.


Subject(s)
GTP-Binding Protein alpha Subunits, Gi-Go/metabolism , Receptors, Cell Surface/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Adenylate Cyclase Toxin , Binding, Competitive , Cells, Cultured , Humans , Iodine Radioisotopes , Ligands , Melatonin/analogs & derivatives , Melatonin/metabolism , Pertussis Toxin , Phenotype , Receptors, Cell Surface/drug effects , Receptors, Cytoplasmic and Nuclear/drug effects , Receptors, Melatonin , Signal Transduction , Virulence Factors, Bordetella/pharmacology
17.
Reprod Nutr Dev ; 39(3): 315-24, 1999.
Article in English | MEDLINE | ID: mdl-10420434

ABSTRACT

Melatonin receptors belong to the superfamily of G protein-coupled receptors. Cloning of Mel1c receptors expressed in Xenopus skin revealed the existence of a polymorphism for these receptors. Heterologous expression of the two allelic isoforms, called Mel1c(alpha) and Mel1c(beta), indicated functional differences in their signalling properties. Both isoforms are coupled to the cAMP and cGMP pathways. However, the alpha isoform is preferentially coupled to the cAMP pathway, whereas the beta isoform couples preferentially to the cGMP pathway. Coupling differences may be explained by the fact that five of the six amino acid substitutions between the two isoforms are localized within intracellular receptor regions potentially involved in G protein coupling. Allelic isoforms were also observed for Mel1a receptors expressed in ovine pars tuberalis, suggesting that polymorphism is a general feature of the melatonin receptor family. We also evaluated the potential of the two human melatonin receptor subtypes, Mel1a and Mel1b, to modulate the cGMP pathway. Melatonin inhibited intracellular cGMP levels in a dose-dependent manner in HEK293 cells transfected with the human Mel1b receptor. This was not the case for HEK293 cells transfected with the human Mel1a receptor. In conclusion, our results indicate that the expression of receptor subtypes and isoforms may permit differential signalling between melatonin receptors.


Subject(s)
Cyclic AMP/physiology , Cyclic GMP/physiology , Melatonin/physiology , Protein Isoforms/physiology , Receptors, Cell Surface/physiology , Receptors, Cytoplasmic and Nuclear/physiology , Signal Transduction/physiology , 1-Methyl-3-isobutylxanthine/pharmacology , Adenylyl Cyclases/metabolism , Alleles , Amino Acid Sequence , Animals , Cell Line , Cloning, Molecular , Colforsin/pharmacology , GTP-Binding Proteins/physiology , Guanylate Cyclase/metabolism , HeLa Cells , Humans , Models, Biological , Molecular Sequence Data , Nitroprusside/pharmacology , Oxadiazoles/pharmacology , Pituitary Gland, Anterior/metabolism , Polymorphism, Genetic , Protein Binding , Protein Isoforms/genetics , Quinoxalines/pharmacology , Receptors, Cell Surface/classification , Receptors, Cell Surface/genetics , Receptors, Cytoplasmic and Nuclear/classification , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Melatonin , Recombinant Fusion Proteins/physiology , Sheep , Signal Transduction/drug effects , Skin/metabolism , Species Specificity , Transfection , Xenopus laevis/genetics
18.
Biochem Pharmacol ; 58(4): 633-9, 1999 Aug 15.
Article in English | MEDLINE | ID: mdl-10413300

ABSTRACT

Cyclic guanosine 3'-5'-monophosphate (cGMP) has recently been shown to constitute a second messenger for Xenopus laevis melatonin Mel1c receptors. To verify whether cGMP levels are also modulated by mammalian melatonin receptors, we cloned the genes encoding the human Mel1a and Mel1b receptor subtypes and expressed them in human embryonic kidney cells. Pharmacological profiles and inhibition of forskolin-stimulated adenosine 3'-5'-cyclic monophosphate levels by melatonin confirmed functional expression of high-affinity melatonin receptors. Mel1b receptor-transfected cells modulated cGMP levels in a dose-dependent manner via the soluble guanylyl cyclase pathway. In contrast, Mel1a receptors had no effect on cGMP levels. These results demonstrate that mammalian melatonin receptors modulate cGMP levels and reveal for the first time differences in signaling between melatonin receptor subtypes, which may explain the necessity to express different receptor subtypes.


Subject(s)
Cyclic GMP/metabolism , Melatonin , Receptors, Cell Surface/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Signal Transduction/physiology , Amino Acid Sequence , Cells, Cultured , Cloning, Molecular , Cyclic AMP/metabolism , Gene Expression , Humans , Molecular Sequence Data , Receptors, Cell Surface/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Melatonin , Sequence Homology, Amino Acid
20.
C R Seances Soc Biol Fil ; 192(4): 659-67, 1998.
Article in French | MEDLINE | ID: mdl-9842470

ABSTRACT

Melatonin receptors belong to the super-family of G protein-coupled receptors. They modulate a large spectrum of physiological functions including regulation of circadian rhythms and seasonal reproduction. Pharmacological evidence suggests the expression of two types of receptors, called Mel1 and Mel2. So far, only Mel1 receptors have been cloned and classified into three subtypes (Mel1A, Mel1B, Mel1C). Mel1 receptors are expressed in the brain, the retina and several other peripheral tissues. All Mel1 subtypes show comparable pharmacological profiles including inhibition of adenylyl cyclase. Cloning and expression of two allelic isoforms of the Mel1 receptor from Xenopus laevis has revealed another signalling pathway, inhibition of cGMP levels via the soluble guanylyl cyclase pathway. The two isoforms are differentially coupled to the cAMP and cGMP pathways indicating the existence of functional differences between melatonin receptors. Future research topics will include cloning of the Mel2 receptor, receptor regulation and the elucidation of melatonin receptor's function in peripheral tissues.


Subject(s)
Receptors, Cell Surface/chemistry , Receptors, Cell Surface/physiology , Receptors, Cytoplasmic and Nuclear/chemistry , Receptors, Cytoplasmic and Nuclear/physiology , Adenylyl Cyclases/metabolism , Amino Acid Sequence , Animals , Brain/physiology , Circadian Rhythm , GTP-Binding Proteins/metabolism , Humans , Molecular Sequence Data , Protein Conformation , Receptors, Melatonin , Retina/physiology , Xenopus laevis
SELECTION OF CITATIONS
SEARCH DETAIL
...